GlassScriptPhysician profile
Peter Marshall Daut
NPI 1952352106
$3,529.59
in general payments reported to CMS, 2019-2025
20 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $86.81 · 2021: $104 · 2022: $393 · 2023: $375 · 2024: $269 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,432.35 | 2019-2023 | Tecnis Iol |
| Biotissue Holdings INC. | $289.67 | 2021-2025 | |
| Glaukos Corporation | $284.00 | 2020-2025 | Idosetr, Istent Infinite, Idose |
| Alcon Vision LLC | $273.86 | 2022-2025 | Hydrus Microstent, Clareon, Unity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $258.74 | 2019 | |
| Bausch & Lomb Americas INC. | $240.98 | 2022-2025 | Vyzulta, Miebo, Scoutpro Osmolarity System |
| Abbvie INC. | $174.24 | 2022-2025 | Durysta |
| Rxsight INC | $132.08 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Stryker Corporation | $112.80 | 2025 | Scopis Ent |
| Tarsus Pharmaceuticals, INC. | $81.12 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $72.95 | 2019-2025 | |
| Eyevance Pharmaceuticals LLC | $32.50 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $25.50 | 2020-2021 | |
| Genentech USA, INC. | $23.04 | 2023 | Vabysmo |
| Amgen INC. | $20.86 | 2025 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $18.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.47 | 2019 | |
| Ocular Therapeutix, INC. | $14.65 | 2024 | Dextenza |
| Optos, INC. | $12.52 | 2020 | |
| Allergan, INC. | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Daut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.